<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210705051792N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-11-01</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of amniotic membrane in compare of Agcoat  in healing of burn wounds</public_title>
      <acronym></acronym>
      <scientific_title>The effect of amniotic membrane in healing of burn wounds in comparison with Ag coat dressing in the burned patients in Isfahan burn center</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-07-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>25</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/57394</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Health service research, Randomization description: In this study random sequence generation perform as minimization and for this manner initially the first case allocated to the first group and the second case also allocated to another group. According to the features of each cases a matched case also choice and include to the groups. For concealment, the cases will be added as lottery, Blinding description: Before transfer to the operation room. It is explained for the patients that their burn ulcer will be dressed as one of two formal manner. In operating room after allocation of each cases to groups finally, dressing will be done. Even after surgery, the patients do not aware of dressing type. In day 7, the patients` dressing will be changed by a nurse who do not participate in the study and the patient will be refer to a researcher(who do not aware of dressing type) for evaluation of variables and these variables will be send for analysis.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Burn.</hc_freetext>
      <i_freetext>Intervention 1: Control group: In this group of patients, after initial resuscitation of burns, in the operating room, according to the extension of the burn, for one session or more, the burnt tissues will be debrided to reach a viable level. The burn wound will be covered by the Ag-coat dressing -Emad brand (which is the brand used by the hospital) as a standard and accepted treatment. Normally, a silver dressing is effective for 7 to 10 days, after which time it will be removed and based on the wound condition, a decision is made on how to continue the treatment, including repetition of the Ag-coat dressing, skin graft, or regular dressing. Finally, three, six and twelve  months after the onset of burn, the patient's wound is evaluated according to clinical criteria as well as the Vancouver chart. Intervention 2: Intervention group: In this group of patients, after initial  resuscitation of burns, in the operating room, based on the extension of the burn, for one session or more, the burnt tissues will be debrided  to reach a viable level. The Life Cell brand (which is the brand used by the hospital) is covered as a new treatment. The amniotic dressing is usually absorbed within 5 to 7 days, after which time the condition of the wound is decided on how to continue the treatment, including skin grafts or regular dressings. Finally, three months and six months after the onset of burn, the patient's wound is evaluated according to clinical criteria as well as the Vancouver chart.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Except of Personal Information of patients all of other is reachable

When:
Every 3 months

To whom:
Academic Researcher

Conditions:
Academic Research

Where to obtain:
Study Correspondent

How to obtain:
Request by E-Mail

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Amin Ghanee Anaraki</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Second Floor, Savaneh hospital, Kave</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8138894948</zip>
        <telephone>+98 31 3345 7670</telephone>
        <email>aminghaneei@yahoo.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Majid Kalbasi Gharavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Second Floor, Savaneh hospital, Kave</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8138894948</zip>
        <telephone>+98 31 3345 7670</telephone>
        <email>kalbasimajid@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Second Degree or More Burn
Patient informed consent to participate in the study</inclusion_criteria>
      <agemin>1 year</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Associated Trauma
Associated Chronic Illness
Pregnancy
Lactation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T30.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Burn of unspecified body region, unspecified degree</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: In this group of patients, after initial resuscitation of burns, in the operating room, according to the extension of the burn, for one session or more, the burnt tissues will be debrided to reach a viable level. The burn wound will be covered by the Ag-coat dressing -Emad brand (which is the brand used by the hospital) as a standard and accepted treatment. Normally, a silver dressing is effective for 7 to 10 days, after which time it will be removed and based on the wound condition, a decision is made on how to continue the treatment, including repetition of the Ag-coat dressing, skin graft, or regular dressing. Finally, three, six and twelve  months after the onset of burn, the patient's wound is evaluated according to clinical criteria as well as the Vancouver chart.</i_keyword>
      <i_keyword>Intervention group: In this group of patients, after initial  resuscitation of burns, in the operating room, based on the extension of the burn, for one session or more, the burnt tissues will be debrided  to reach a viable level. The Life Cell brand (which is the brand used by the hospital) is covered as a new treatment. The amniotic dressing is usually absorbed within 5 to 7 days, after which time the condition of the wound is decided on how to continue the treatment, including skin grafts or regular dressings. Finally, three months and six months after the onset of burn, the patient's wound is evaluated according to clinical criteria as well as the Vancouver chart.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The Vancouver Scar Scale. Timepoint: First week, First month, Third month, Sixth Month. Method of measurement: According to Chart and Scale between 0-13.</prim_outcome>
      <prim_outcome>Hospitalization. Timepoint: From admission to discharge. Method of measurement: The days according to hospitalization file since the first day to the discharge day.</prim_outcome>
      <prim_outcome>Treatment cost. Timepoint: Admission Duration. Method of measurement: Cost in Rials based on the final bill of the hospital.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-06-25</approval_date>
        <contact_name>Ethics committee of isfahan University of Medical Sciences</contact_name>
        <contact_address>Hezar Jarib Ave., Isfahan University of Medical Sciences Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
